Published in AIDS on September 12, 2007
CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS (2008) 5.30
Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384. Clin Infect Dis (2009) 3.39
HIV infection and the risk of cancers with and without a known infectious cause. AIDS (2009) 3.13
Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study. Clin Trials (2012) 2.71
Development of diagnostic criteria for serious non-AIDS events in HIV clinical trials. HIV Clin Trials (2010) 1.75
Towards an HIV-1 cure: measuring the latent reservoir. Trends Microbiol (2015) 1.73
Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. Br J Cancer (2008) 1.70
An internationally generalizable risk index for mortality after one year of antiretroviral therapy. AIDS (2013) 1.64
Motivation and patch treatment for HIV+ smokers: a randomized controlled trial. Addiction (2009) 1.61
Malignancies in HIV/AIDS: from epidemiology to therapeutic challenges. AIDS (2014) 1.41
Predicting risk of cancer during HIV infection: the role of inflammatory and coagulation biomarkers. AIDS (2013) 1.34
Exposure to antiretroviral therapy and risk of cancer in HIV-infected persons. AIDS (2012) 1.07
HIV and cancer in Germany. Dtsch Arztebl Int (2011) 1.05
Incidence and risk factors of HIV-related non-Hodgkin's lymphoma in the era of combination antiretroviral therapy: a European multicohort study. Antivir Ther (2009) 1.04
Incidence of non-AIDS-defining cancer in antiretroviral treatment-naïve subjects after antiretroviral treatment initiation: an ACTG longitudinal linked randomized trials analysis. Oncology (2011) 0.99
HIV-associated bladder cancer: a case series evaluating difficulties in diagnosis and management. BMC Urol (2009) 0.99
Evolving spectrum and incidence of non-AIDS-defining malignancies. Curr Opin HIV AIDS (2009) 0.99
Impact of antiretroviral therapy on the incidence of Kaposi's sarcoma in resource-rich and resource-limited settings. Curr Opin Oncol (2012) 0.97
Cutaneous malignancies among HIV-infected persons. Arch Intern Med (2009) 0.96
Cancer incidence in a Nationwide HIV/AIDS patient cohort in Taiwan in 1998-2009. J Acquir Immune Defic Syndr (2014) 0.96
Risk factors for Kaposi's sarcoma among HIV-positive individuals in a case control study in Cameroon. Cancer Epidemiol (2014) 0.95
Factors contributing to risk for cancer among HIV-infected individuals, and evidence that earlier combination antiretroviral therapy will alter this risk. Curr Opin HIV AIDS (2014) 0.93
Human immunodeficiency virus-associated lung cancer in the era of highly active antiretroviral therapy. Cancer (2011) 0.88
Do antiretrovirals reduce the risk of non-AIDS-defining malignancies? Curr Opin HIV AIDS (2009) 0.88
Inferiority of IL-2 alone versus IL-2 with HAART in maintaining CD4 T cell counts during HAART interruption: a randomized controlled trial. AIDS (2009) 0.86
Radiotherapy for patients with the human immunodeficiency virus: are special precautions necessary? Cancer (2010) 0.85
Immediate Antiretroviral Therapy Reduces Risk of Infection-Related Cancer During Early HIV Infection. Clin Infect Dis (2016) 0.83
Relationship of immunologic response to antiretroviral therapy with non-AIDS defining cancer incidence. AIDS (2014) 0.81
Combination antiretroviral therapy and cancer risk. Curr Opin HIV AIDS (2017) 0.80
In vitro naïve T cell proliferation failure predicts poor post-immunization responses to neoantigen, but not recall antigens, in HIV-infection. Clin Immunol (2010) 0.80
CD4+ T-cell-guided structured treatment interruptions of antiretroviral therapy in HIV disease: projecting beyond clinical trials. Antivir Ther (2010) 0.79
Developing clinical strength-of-evidence approach to define HIV-associated malignancies for cancer registration in Kenya. PLoS One (2014) 0.79
Human papillomavirus-related diseases in HIV-infected individuals. Curr Opin Oncol (2008) 0.78
Clinical characteristics of Japanese lung cancer patients with human immunodeficiency virus infection. Int J Clin Oncol (2011) 0.77
Cancer prevention in HIV-infected populations. Semin Oncol (2015) 0.77
Incidence and risk of lung cancer in HIV-infected patients. J Cancer Res Clin Oncol (2013) 0.76
HIV-induced immune activation: pathogenesis and clinical relevance - summary of a workshop organized by the German AIDS Society (DAIG e.v.) and the ICH Hamburg, Hamburg, Germany, November 22, 2008. Eur J Med Res (2010) 0.76
Lung cancer in HIV-infected patients in the combination antiretroviral treatment era. Transl Lung Cancer Res (2015) 0.75
Increased Natural Killer Cell Activation in HIV-Infected Immunologic Non-Responders Correlates with CD4+ T Cell Recovery after Antiretroviral Therapy and Viral Suppression. PLoS One (2017) 0.75
Long-term nitrite inhalant exposure and cancer risk in MSM. AIDS (2017) 0.75
Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med (2015) 15.06
Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med (2008) 13.72
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61
Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis (2011) 7.41
Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA (2003) 7.35
The prevention and treatment of missing data in clinical trials. N Engl J Med (2012) 6.92
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med (2003) 5.79
Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med (2005) 5.54
Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis (2010) 5.35
CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS (2008) 5.30
Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet (2009) 5.23
Short-course antiretroviral therapy in primary HIV infection. N Engl J Med (2013) 4.82
Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. N Engl J Med (2003) 4.27
Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA (2003) 3.71
Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS One (2012) 3.68
Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis (2005) 3.52
Association of single measurements of dipstick proteinuria, estimated glomerular filtration rate, and hematocrit with 25-year incidence of end-stage renal disease in the multiple risk factor intervention trial. J Am Soc Nephrol (2006) 3.51
Care of patients with hepatitis C and HIV co-infection. AIDS (2004) 3.46
Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up. J Infect Dis (2008) 3.35
HIV infection and the risk of cancers with and without a known infectious cause. AIDS (2009) 3.13
Pulse pressure and cardiovascular disease-related mortality: follow-up study of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA (2002) 2.96
Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. Antivir Ther (2008) 2.93
Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death. J Infect Dis (2011) 2.88
Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial. J Infect Dis (2013) 2.82
Microseizures and the spatiotemporal scales of human partial epilepsy. Brain (2010) 2.81
Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study. Clin Trials (2012) 2.71
Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. AIDS (2003) 2.66
Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol (2008) 2.38
Evidence-based clinical practice guidelines for integrative oncology: complementary therapies and botanicals. J Soc Integr Oncol (2009) 2.35
Long-term cardiovascular mortality among middle-aged men with gout. Arch Intern Med (2008) 2.32
British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med (2012) 2.24
Increasing prevalence of HIV-1 subtype A in Greece: estimating epidemic history and origin. J Infect Dis (2007) 2.21
Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection. J Acquir Immune Defic Syndr (2011) 2.21
Smoking-related health risks among persons with HIV in the Strategies for Management of Antiretroviral Therapy clinical trial. Am J Public Health (2010) 2.21
Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection. J Infect Dis (2009) 2.20
Impact of hepatitis B virus infection on the progression of AIDS and mortality in HIV-infected individuals: a cohort study and meta-analysis. Clin Infect Dis (2009) 2.13
Monitoring the quality of conduct of clinical trials: a survey of current practices. Clin Trials (2011) 2.08
It's time for clinicians to reconsider their proscription against the use of soyfoods by breast cancer patients. Oncology (Williston Park) (2013) 2.07
Economic recession and emergence of an HIV-1 outbreak among drug injectors in Athens metropolitan area: a longitudinal study. PLoS One (2013) 2.06
The global spread of hepatitis C virus 1a and 1b: a phylodynamic and phylogeographic analysis. PLoS Med (2009) 2.06
Methodological issues in cohort studies that relate sodium intake to cardiovascular disease outcomes: a science advisory from the American Heart Association. Circulation (2014) 2.05
HBV viremia in newborns of HBsAg(+) predominantly Caucasian HBeAg(-) mothers. J Clin Virol (2010) 2.04
Race/ethnicity, income, major risk factors, and cardiovascular disease mortality. Am J Public Health (2005) 2.02
HIV infection, immunodeficiency, viral replication, and the risk of cancer. Cancer Epidemiol Biomarkers Prev (2011) 2.02
Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS (2007) 2.00
Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients. AIDS (2007) 1.98
Predicted effects of treatment for HCV infection vary among European countries. Gastroenterology (2012) 1.89
Primary HIV-1 infection sets the stage for important B lymphocyte dysfunctions. AIDS (2005) 1.87
Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr (2005) 1.87
Relation of triglyceride levels, fasting and nonfasting, to fatal and nonfatal coronary heart disease. Arch Intern Med (2003) 1.82
Melanocortin receptor-1 gene polymorphisms and the risk of cutaneous melanoma in a low-risk southern European population. J Invest Dermatol (2006) 1.80
Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection. J Infect Dis (2005) 1.80
Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks. Int J Epidemiol (2002) 1.79
Submandibular gland biopsy for the diagnosis of Parkinson disease. J Neuropathol Exp Neurol (2013) 1.77
Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study. AIDS (2002) 1.74
The evaluation of subcutaneous proleukin (interleukin-2) in a randomized international trial: rationale, design, and methods of ESPRIT. Control Clin Trials (2002) 1.73
End-stage liver disease in persons with hemophilia and transfusion-associated infections. Blood (2002) 1.73
Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther (2004) 1.72
Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology (2007) 1.72
Incidence of type 2 diabetes in the randomized multiple risk factor intervention trial. Ann Intern Med (2005) 1.71
Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma: higher incidence and mortality in Africa than in the UK. AIDS (2013) 1.71
Episodic antiretroviral therapy increases HIV transmission risk compared with continuous therapy: results of a randomized controlled trial. J Acquir Immune Defic Syndr (2008) 1.70
A randomized factorial trial comparing 4 treatment regimens in treatment-naive HIV-infected persons with AIDS and/or a CD4 cell count <200 cells/μL in South Africa. J Infect Dis (2010) 1.69
Lipoprotein particle subclasses, cardiovascular disease and HIV infection. Atherosclerosis (2009) 1.66
Fifty years of multicentric Castleman's disease. Acta Oncol (2004) 1.65
HIV-1 subtype diversity in Minnesota. J Infect Dis (2005) 1.63
When to start therapy for HIV infection: a swinging pendulum in search of data. Ann Intern Med (2003) 1.63
Optimal use of maraviroc in clinical practice. AIDS (2008) 1.60
Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden. J Infect Dis (2011) 1.59
High Prevalence of Echocardiographic Abnormalities among HIV-infected Persons in the Era of Highly Active Antiretroviral Therapy. Clin Infect Dis (2010) 1.58
Concentration-controlled compared with conventional antiretroviral therapy for HIV infection. AIDS (2002) 1.58
Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach. Retrovirology (2009) 1.58
HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era. J Clin Oncol (2012) 1.55
ZIP-code-based versus tract-based income measures as long-term risk-adjusted mortality predictors. Am J Epidemiol (2006) 1.53
Primary esophageal carcinoma in the era of highly active antiretroviral therapy. Arch Intern Med (2010) 1.52
Transmission of hepatitis C virus among HIV-positive homosexual men and response to a 24-week course of pegylated interferon and ribavirin. J Acquir Immune Defic Syndr (2005) 1.50
Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks. J Acquir Immune Defic Syndr (2005) 1.50
Poor initial CD4+ recovery with antiretroviral therapy prolongs immune depletion and increases risk for AIDS and non-AIDS diseases. J Acquir Immune Defic Syndr (2008) 1.49
Persistent HIV-1 infection of natural killer cells in patients receiving highly active antiretroviral therapy. Proc Natl Acad Sci U S A (2002) 1.49
KSHV-encoded miRNAs target MAF to induce endothelial cell reprogramming. Genes Dev (2010) 1.48
Long-term effects of chlorthalidone versus hydrochlorothiazide on electrocardiographic left ventricular hypertrophy in the multiple risk factor intervention trial. Hypertension (2011) 1.46
High-density lipoprotein particles and markers of inflammation and thrombotic activity in patients with untreated HIV infection. J Infect Dis (2010) 1.46
Plasma HHV8 DNA predicts relapse in individuals with HIV-associated multicentric Castleman disease. Blood (2011) 1.46
Analysis of HIV-1- and CMV-specific memory CD4 T-cell responses during primary and chronic infection. Blood (2002) 1.45
Demographic, clinical, and virologic characteristics of African-born persons with HIV/AIDS in a Minnesota hospital. AIDS Patient Care STDS (2007) 1.45
Blockade of HERG channels by HIV protease inhibitors. Lancet (2005) 1.44
Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: a cohort and case-control study. J Acquir Immune Defic Syndr (2004) 1.42
Pilot study of vascular health in survivors of osteosarcoma. Pediatr Blood Cancer (2013) 1.42